Valbiotis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Valbiotis hat ein Gesamteigenkapital von €16.8M und eine Gesamtverschuldung von €5.0M, was einen Verschuldungsgrad von 29.6% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen €25.9M bzw. €9.0M.

Wichtige Informationen

29.6%

Verhältnis von Schulden zu Eigenkapital

€4.99m

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	€18.55m
Eigenkapital	€16.84m
Gesamtverbindlichkeiten	€9.03m
Gesamtvermögen	€25.86m

Jüngste Berichte zur Finanzlage

Recent updates

Is Valbiotis (EPA:ALVAL) A Risky Investment?

Jun 20

Rock star Growth Puts Valbiotis (EPA:ALVAL) In A Position To Use Debt

May 09

Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?

May 10

Valbiotis SA (EPA:ALVAL) Is Expected To Breakeven In The Near Future

Mar 08

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: ALVALDie kurzfristigen Aktiva des Unternehmens (€23.5M) übersteigen seine kurzfristigen Passiva (€4.8M).

Langfristige Verbindlichkeiten: ALVALDie kurzfristigen Vermögenswerte des Unternehmens (€23.5M) übersteigen seine langfristigen Verbindlichkeiten (€4.2M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: ALVAL über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: ALVAL Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 35.6% auf 29.6% zurückgegangen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: ALVAL auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als ein Jahr verfügt.

Vorhersage Cash Runway: ALVAL verfügt über eine ausreichende Liquiditätsreserve für 2.3 Jahre, wenn der freie Cashflow weiterhin mit historischen Raten von 17.2% pro Jahr abnimmt.

Valbiotis Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Valbiotis (EPA:ALVAL) A Risky Investment?

Rock star Growth Puts Valbiotis (EPA:ALVAL) In A Position To Use Debt

Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?

Recent updates

New minor risk - Profitability

Price target increased by 25% to €6.35

Is Valbiotis (EPA:ALVAL) A Risky Investment?

Consensus EPS estimates fall by 18%

Price target decreased by 13% to €8.60

Valbiotis SA, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings released

New minor risk - Shareholder dilution

New minor risk - Profitability

Price target decreased by 10% to €10.60

Consensus revenue estimates decrease by 30%

Valbiotis SA has filed a Follow-on Equity Offering in the amount of €15.000001 million.

Valbiotis SA Presents the Full Results of the Phase II/III REVERSE-IT Study: Impressive Efficacy of TOTUM 63 Against Prediabetes and the Early Stages of Type 2 Diabetes, a First for a Non-drug Active Substance

Consensus EPS estimates fall by 99%

Consensus revenue estimates decrease by 32%

Price target increased by 7.5% to €11.93

Consensus EPS estimates upgraded to €0.65 loss

Valbiotis Announces the Large Success of the REVERSE-IT International Multicentric Phase II/III Clinical Study on TOTUM-63

Rock star Growth Puts Valbiotis (EPA:ALVAL) In A Position To Use Debt

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released

Valbiotis Announces Positive Results in the Bioavailability and Mode of Action TOTUM--854 Clinical Study, Against High Blood Pressure

Forecast breakeven date pushed back to 2024

Price target decreased to €11.83

Forecast to breakeven in 2023

Valbiotis SA announced that it has received €9.7 million in funding

Valbiotis SA Presents Additional Positive Results from the HEART Clinical Study on TOTUM•070 for Hypercholesterolemia

Consensus forecasts updated

Forecast breakeven date moved forward to 2023

Price target decreased to €13.67

First half 2022 earnings released

Consensus forecasts updated

Forecast to breakeven in 2023

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Appoints Frédéric PELONG to Board of Directors

Valbiotis Announces Completion of Recruitment for the Phase Ii/Iii Reverse-It Clinical Study with Totum•63 Against Prediabetes, in Partnership with Nestlé Health Science

Consensus forecasts updated

Valbiotis Announces the Major Success of the Phase II Heart Clinical Study the Patented Plant-Based Active Substance Totum•070 Proves Its Efficacy Against Hypercholesterolemia, A Cardiovascular Risk Factor

Is Valbiotis (EPA:ALVAL) Using Debt In A Risky Way?

Forecast to breakeven in 2023

No independent directors

Valbiotis SA Announces the Positive Results of Its Clinical Study on the Bioavailability and Mode of Action of TOTUM•070, Against Hypercholesterolemia

Consensus forecasts updated

Full year 2021 earnings: Revenues miss analyst expectations

Valbiotis Announces Board of Directors Changes

Valbiotis SA to Report Fiscal Year 2021 Results on Mar 15, 2022

Valbiotis Announces Approval to Launch the Two Phase II/III Insight and Insight 2 Clinical Studies, the Last Step in the Development of Totum•854 for the Reduction of Blood Pressure

Consensus forecasts updated

Forecast to breakeven in 2023

Valbiotis Submits to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents its Comprehensive Clinical Development Plan

First half 2021 earnings released

Valbiotis Announces the Publication of the First Scientific Papers on TOTUM•63 in Three International Journals, Elucidating Its Multitarget Mode of Action

Full year 2020 earnings released

Valbiotis SA to Report First Half, 2021 Results on Sep 30, 2021

Valbiotis Selected to Present TOTUM-854 Results on Arterial Hypertension

Valbiotis SA (EPA:ALVAL) Is Expected To Breakeven In The Near Future

Valbiotis SA Announces the First Patient’s First Visit in the Phase II HEART Clinical Study on TOTUM-070 and Steps up Its Research Program Against Hypercholesterolemia in 2021

Valbiotis Authorizes to Launch Heart, the Phase II Multi-Center Clinical Study with TOTUM-070, for the Reduction of Blood LDL-Cholesterol Levels

New 90-day high: €7.80

New 90-day high: €6.90

New 90-day high: €6.60

VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART

New 90-day high: €4.85

VALBIOTIS Announces the Selection of 3 Studies on TOTUM-63 by the European Association for the Study of Diabetes

New 90-day high: €4.83

Valbiotis SA announced that it has received €1.999998 million in funding from Amiral Gestion SA

New 90-day high - €4.66

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Liquiditätsreserve-Analyse

Entdecken Sie finanziell stabile Unternehmen